GlobeNewswire

Compuware zAdviser Delivers Actionable Analytic Insight to Continuously Improve Quality, Velocity and Efficiency on the Mainframe

Dela

Innovative Machine Learning Helps IT Leaders Pinpoint Opportunities to Boost DevOps Processes and Development Outcomes

 
  • Enterprises dependent on mainframe applications must aggressively improve DevOps quality, velocity and efficiency-even as responsibilities shift to less experienced internal teams and/or outsourcing partners.

  • Compuware is introducing zAdviser, a free product that leverages machine learning to help IT leaders make smarter data-driven decisions to drive continuous improvement of mainframe DevOps.

  • zAdviser identifies patterns that impact quality, velocity and efficiency as they pertain to mainframe development by analyzing a customer's Compuware product usage data and DevOps key performance indicators (KPIs).  

  • zAdviser is fueled by the ongoing collaboration between customers and Compuware, where customers contribute their relevant DevOps data and Compuware contributes their mainframe expertise and machine learning insights.

DETROIT, April 03, 2018 (GLOBE NEWSWIRE) -- Compuware today announced zAdviser, an innovative product that uses machine learning to continuously measure and improve an organization's mainframe DevOps processes and development outcomes. Based on key performance indicators (KPIs), zAdviser measures application quality, as well as development velocity and the efficiency of a development team-empowering enterprise IT leaders to make evidence-based decisions in support of their continuous improvement efforts. zAdviser is free for Compuware customers on current maintenance.

The KPIs were developed based on extensive research with customers and align with those published in the 2018 Forrester report, "Use Four Key Categories To Measure What Matters In Continuous Deployment."

zAdviser leverages a set of analytic models that uncover correlations between mainframe developer behaviors and mainframe DevOps KPIs. These correlations represent the best available empirical evidence regarding the impact of process, training and tooling decisions on digital business outcomes. With this empirical evidence and associated recommendations, managers can make high-impact decisions about their mainframe DevOps methods with vastly improved speed and confidence.

Enterprises that outsource mainframe development can also reap significant value from zAdviser by using the analytical results to continuously achieve better business outcomes over time.

Improvements in mainframe DevOps is an imperative for large enterprises, which are becoming more dependent on mainframe applications-not less. According to a recent Forrester Consulting study commissioned by Compuware, 57 percent of enterprises with a mainframe run more than half of their business-critical workloads on the platform. That percentage is expected to increase to 64 percent by 2019, while at the same time enterprises are failing to replace the expert mainframe workforce they have lost by attrition.

According to the study, "As mainframe workload increases-driven by modern analytics, blockchain and more mobile activity hitting the platform-customer-obsessed companies should seek to modernize application delivery and remove roadblocks to innovation."

The Forrester Consulting study also highlights the importance of responding to these challenges with empirical insight: "KPIs like mean lead time, number of epics per deployment, and metrics that drive automation will harness velocity and efficiency, even as the skills gap of the workforce expands." The full study can be accessed here.

Compuware has been helping their customers qualify, quantify and increase the value derived from their Compuware products through its Value Improvement Program (VIP) for over 15 years. zAdviser is the next step in the evolution of the VIP and evidence-based mainframe process improvement, leveraging these years of experience helping enterprises modernize mainframe DevOps and improve mainframe staff performance.

zAdviser data inputs include both 1) metrics captured from Compuware tools, including behavioral data relating to feature utilization and 2) data captured from the customer's DevOps toolchain.

By aggregating input from customer sites across industries and around the world, Compuware is building the industry's richest repository of mainframe DevOps data-which combined with advanced machine learning methods generates unmatched insight for enterprise IT leaders.

"Our mainframe applications continue to play a critical role in delivering an excellent customer experience," said Steve Kalkowski, Assistant Vice President, The Hartford. "A product like Compuware zAdviser will give us the advanced analytics we need to drive our efforts towards improving developer speed and quality as we transition to an agile delivery model."

Compuware today also announced a new ThruPut Manager web interface that provides mainframe staff with visually intuitive insight into how batch jobs are being initiated and executed-as well as the impact of those jobs on mainframe software licensing costs.

"Enterprises cannot afford to be even slightly complacent about the speed and excellence with which they update and evolve the core business logic of their mainframe applications," said Compuware CEO Chris O'Malley. "With zAdviser, Compuware is now offering a powerful, fact-based resource for IT leaders at the world's largest corporations to lead their critical mainframe modernization efforts-and to thereby sustainably derive maximum business value from their investments in mainframe hardware, applications and talent."

To learn more about zAdviser and get involved, visit us here.

Compuware Corporation
Compuware empowers the world's largest companies to excel in the digital economy by fully leveraging their high-value mainframe investments. We do this by delivering highly innovative solutions that uniquely enable IT professionals with mainstream skills to manage mainframe applications, data, and platform operations. Learn more at compuware.com .

Follow us on:

Press Contact
Kristina LeBlanc, The Medialink Group, kristinawleblanc@gmail.com, (508) 930-5636
Mary McCarthy, Public Relations Manager, Compuware, mary.mccarthy@compuware.com, (313) 227-7088

For Sales and Marketing Information
Compuware Corporation, One Campus Martius, Detroit MI 48226, 800-266-7892, www.compuware.com.

Copyright © 2018, Compuware Corporation. All rights reserved. The Compuware products and services listed within this release are trademarks or registered trademarks of Compuware Corporation.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Compuware Corporation via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum